Literature DB >> 8207817

Functional exchange of an oncoretrovirus and a lentivirus matrix protein.

C A Deminie1, M Emerman.   

Abstract

To map functional domains in the retroviral Gag protein we have constructed chimeric viruses where regions of the murine leukemia virus (MuLV) Gag protein have been replaced with analogous sequences from human immunodeficiency virus type 1 (HIV-1). Here we describe the chimeric virus MuLV(MAHIV) which contains the HIV-1 matrix (MA) protein in place of the MuLV MA. MuLV(MAHIV) is infectious but grows at a reduced rate compared with wild-type MuLV. We found that the partial defect in replication of the chimeric virus is at a late stage in the viral life cycle. The MuLV(MAHIV) Gag proteins are distributed aberrantly within cells and are not associated with cellular membranes. Unlike MuLV, HIV-1 is able to integrate into growth-arrested cells. Incorporation of the HIV-1 MA, which is known to play a role in infection of nondividing cells, does not enable MuLV(MAHIV) to be expressed in growth-arrested cells. While it possesses no amino acid homology, we found that the HIV-1 MA can efficiently replace the MuLV matrix protein in infection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8207817      PMCID: PMC236369     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  33 in total

1.  Unmyristylated Moloney murine leukemia virus Pr65gag is excluded from virus assembly and maturation events.

Authors:  A M Schultz; A Rein
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

2.  Form, function, and use of retroviral gag proteins.

Authors:  J W Wills; R C Craven
Journal:  AIDS       Date:  1991-06       Impact factor: 4.177

3.  Assembly of gag-beta-galactosidase proteins into retrovirus particles.

Authors:  T A Jones; G Blaug; M Hansen; E Barklis
Journal:  J Virol       Date:  1990-05       Impact factor: 5.103

4.  The rev gene product of the human immunodeficiency virus affects envelope-specific RNA localization.

Authors:  M Emerman; R Vazeux; K Peden
Journal:  Cell       Date:  1989-06-30       Impact factor: 41.582

5.  A nucleoprotein complex mediates the integration of retroviral DNA.

Authors:  B Bowerman; P O Brown; J M Bishop; H E Varmus
Journal:  Genes Dev       Date:  1989-04       Impact factor: 11.361

6.  Myristylation site in Pr65gag is essential for virus particle formation by Moloney murine leukemia virus.

Authors:  A Rein; M R McClure; N R Rice; R B Luftig; A M Schultz
Journal:  Proc Natl Acad Sci U S A       Date:  1986-10       Impact factor: 11.205

7.  High-efficiency transformation of mammalian cells by plasmid DNA.

Authors:  C Chen; H Okayama
Journal:  Mol Cell Biol       Date:  1987-08       Impact factor: 4.272

8.  Rous sarcoma virus p19 and gp35 can be chemically crosslinked to high molecular weight complexes. An insight into virus assembly.

Authors:  A Gebhardt; J V Bosch; A Ziemiecki; R R Friis
Journal:  J Mol Biol       Date:  1984-04-05       Impact factor: 5.469

9.  High level transient expression of a chloramphenicol acetyl transferase gene by DEAE-dextran mediated DNA transfection coupled with a dimethyl sulfoxide or glycerol shock treatment.

Authors:  M A Lopata; D W Cleveland; B Sollner-Webb
Journal:  Nucleic Acids Res       Date:  1984-07-25       Impact factor: 16.971

10.  Mutations in gag proteins P12 and P15 of Moloney murine leukemia virus block early stages of infection.

Authors:  S Crawford; S P Goff
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

View more
  13 in total

1.  High-throughput, library-based selection of a murine leukemia virus variant to infect nondividing cells.

Authors:  Julie H Yu; David V Schaffer
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 2.  Vectors for cancer gene therapy.

Authors:  J Zhang; S J Russell
Journal:  Cancer Metastasis Rev       Date:  1996-09       Impact factor: 9.264

3.  Chimeric human immunodeficiency virus type 1 containing murine leukemia virus matrix assembles in murine cells.

Authors:  Margaret Reed; Roberto Mariani; Liana Sheppard; Katja Pekrun; Nathaniel R Landau; Nay-Wei Soong
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  Solution properties of murine leukemia virus gag protein: differences from HIV-1 gag.

Authors:  Siddhartha A K Datta; Xiaobing Zuo; Patrick K Clark; Stephen J Campbell; Yun-Xing Wang; Alan Rein
Journal:  J Virol       Date:  2011-09-14       Impact factor: 5.103

5.  Transduction of interphase cells by avian sarcoma virus.

Authors:  Richard A Katz; James G Greger; Kristen Darby; Pamela Boimel; Glenn F Rall; Anna Marie Skalka
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

6.  Replacement of murine leukemia virus readthrough mechanism by human immunodeficiency virus frameshift allows synthesis of viral proteins and virus replication.

Authors:  Marie-Noëlle Brunelle; Léa Brakier-Gingras; Guy Lemay
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

7.  The retroviral capsid domain dictates virion size, morphology, and coassembly of gag into virus-like particles.

Authors:  Danso Ako-Adjei; Marc C Johnson; Volker M Vogt
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

8.  Capsid is a dominant determinant of retrovirus infectivity in nondividing cells.

Authors:  Masahiro Yamashita; Michael Emerman
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

9.  The Mason-Pfizer monkey virus internal scaffold domain enables in vitro assembly of human immunodeficiency virus type 1 Gag.

Authors:  Michael Sakalian; Stephanie S Dittmer; A Dustin Gandy; Nathan D Rapp; Ales Zábranský; Eric Hunter
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

10.  Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.

Authors:  Bindong Liu; Xianghui Yu; Kun Luo; Yunkai Yu; Xiao-Fang Yu
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.